65,437 trials
Myopia
Primary: Overall Comfort — 9.5; 7.9; 9.0; 8.6 Units on a scale
Respiratory Failure
Primary: Duration of Weaning Time — 0.18; 0.05 days
Congestive Heart Failure
Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…
Breast Neoplasms
Primary: Number of Participants With Progression Free Survival (PFS) in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast Cancer as…
Multiple Myeloma · Leukemia · Lymphoma
Primary: Number of Participants With Engraftment — 27 participants
Hepatitis C, Chronic
Primary: Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase — 32; 97 participants — p=0.0202
Sarcoma · Oral Mucositis
Primary: Cumulative Incidence Rate of Oral Mucositis — 44; 88; 13; 51 Percentage of Participants — p=<0.001
HIV Infections
Primary: Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline — 4.873; 4.840; 4.886 log10 copies/milliliter(log10 copies/mL)
Asthmatic Smokers · Non-asthmatic Smokers
Primary: Sputum Neutrophil Percentages — 86.00; 72.53; 89.33; 79.84 percentage of neutrophils
Benign Prostatic Hyperplasia
Primary: Pharmacokinetics: Area Under the Concentration Curve (AUC) for Tadalafil and Metabolite IC710 — 1410; 1340; 2710; 3410 nanograms*hour/milliliter (ng*hr/mL)
Crohn's Disease
Primary: Diagnostic Yield in Suspected Crohn's Patients (CE Prior to IC vs. IC and SBFT) — 97.3; 57.3 percentage of yield — p=<0.0001
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants With a Tumor Response (Objective Tumor Response Rate) — 38.5 percentage of participants
Rheumatoid Arthritis
Primary: Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 3 — 13.4 Percentage of participants
Anemia
Primary: Haemoglobin Level — 88.3; 89.2; 88.4; 89.6 g/L — p=<0.05
Chronic Refractory Neuropathic Pain
Primary: Number of Subjects Reporting At Least 1 Treatment-Emergent Adverse Event (TEAE) During The Treatment Period. — 7 participants